Clinical trials: Renal Allograft
Kidney Diseases
Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion
This study is design to compare two different strategies aiming to lessen the degree of the ongoing process of allograft injury either by removing tacrolimus from the maintenance immunosuppressive protocol or by reducing…
- Trial name
- NCT00443508
- Testing
- adding Certican to therapy, reducing Tacrolimus
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Rabin Medical Center
Reperfusion Injury, Hypothermic Oxygenated Machine Perfusion
Hypothermic Oxygenated Machine Perfusion of Extended Criteria Kidney Allografts From Brain Death Donors
Kidney transplantation (KT) has emerged as the mainstay of treatment for end-stage kidney disease. In an effort to address the widening gap between demand and supply of donor organs, there has been an increase in the numbers of…
- Trial name
- NCT03378817
- Testing
- HOPE, Conventional cold storage
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- University Hospital, Aachen
End Stage Renal Failure
Gengraf Conversion Study in Stable Renal Allograft Transplant Recipients
The purpose of this study is to establish the therapeutic equivalence of Gengraf® with the standard treatment Neoral® for a treatment period of 6 months in stable renal allograft transplant recipients with respect to drug levels…
- Trial name
- NCT01990118
- Testing
- Neoral, Gengraf® capsule containing 25mg or 100mg cyclosporine
- Where
- Malaysia
- Volunteers
- 106 people
- Sponsor
- Penang Hospital, Malaysia
Glomerular Filtration Rate, Chronic Allograft Nephropathy
Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients
The objective of this study is to examine the effect on allograft function and histology of converting African American renal transplant recipients with chronic allograft nephropathy (CAN) from a tacrolimus-based regimen to a…
- Trial name
- NCT00999258
- Testing
- sirolimus
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Temple University
Kidney Transplant Failure and Rejection
Assessment of QSant™ for Underlying Allograft Rejection
The AQUA registry is a multi-center observational study to assess the clinical management of kidney transplant recipients (KTRs) with use of the QSant test.
- Trial name
- AQUA (NCT05282966)
- Testing
- QSant-TM Urine Test
- Volunteers
- 4,000 people
- Sponsor
- NephroSant
Transplantation, Organ
A Study of Belimumab in the Prevention of Kidney Transplant Rejection
Kidney transplantation is the best treatment for many patients with kidney failure. Sometimes a transplanted kidney is rejected by the patient's immune system.
- Trial name
- NCT01536379
- Testing
- Belimumab
- Where
- 2 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Graft Rejection, Kidney Failure
Study Comparing Two Immunosuppressive Regimens in De Novo Renal Allograft Recipients
Evaluate renal graft function (based on the calculated Glomerular Filtration Rate) at 12 months after transplantation in patients receiving either a regimen of sirolimus plus mycophenolate mofetil following an antibody induction…
- Conditions
- Graft Rejection, Kidney Failure, Kidney Transplantation
- Trial name
- NCT00261820
- Testing
- tacrolimus, mycophenolate mofetil, methylprednisolone
- Volunteers
- 160 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Bleeding, Transplant, Kidney
Bleeding Prevention With Desmopressin for Allograft Kidney Biopsies
The goal of this study is to evaluate the efficacy and safety of desmopressin to prevent bleeding after percutaneous renal graft biopsy in patients at high risk of bleeding.
- Conditions
- Bleeding, Transplant, Kidney, Desmopressin, Kidney Biopsy
- Trial name
- BRIDGE (NCT06622187)
- Testing
- Desmopressin (DDAVP), Sodium Chloride
- Where
- Brazil
- Volunteers
- 96 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Kidney Transplantation
Trial of Rituximab Given Pre-Transplant to Sensitised Live Donor Kidney Recipients
About one third of prospective kidney transplant recipients have antibodies in their blood directed against the tissues of their only available kidney donor.
- Trial name
- RAPTURE (NCT00371904)
- Testing
- Rituximab, Standard Care
- Where
- 3 sites in Australia
- Volunteers
- 192 people
- Sponsor
- Hunter and New England Health
Kidney Transplant
Long-term Follow-up of Spare the Nephron (STN) Patients
Allograft nephropathy is the most common cause of allograft failure following kidney transplantation. Among putative etiologies, cumulative exposure to calcineurin inhibitors may be one of the important progression factors.
- Trial name
- STN (NCT01126333)
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- University of Maryland, Baltimore
Acute Graft Rejection, Chronic Allograft Nephropathy
Study Cyclosporine (CsA) Versus Tacrolimus (Tacro) After Campath Induction in Kidney Transplantation
After alemtuzumab induction, followed with kidney transplantation, patients will be randomly assigned to receive either tacrolimus or cyclosporine microemulsion in combination with mycophenolates.
- Conditions
- Acute Graft Rejection, Chronic Allograft Nephropathy, Polyomavirus-related Transplant Nephropathy
- Trial name
- RSCS-Campath (NCT01346397)
- Testing
- cyclosporine or tacrolimus
- Where
- Russia
- Volunteers
- 170 people
- Sponsor
- Russian Academy of Medical Sciences
Kidney Transplantation
Genomics of Chronic Renal Allograft Rejection (The GoCAR Study)
Doctors have had success preventing certain types of kidney transplant rejection by suppressing the immune system. However, an individual's genetic make-up and the strength of an immune response to a transplant may also determine…
- Trial name
- NCT00611702
- Testing
- Kidney biopsy
- Where
- 5 sites in United States, Australia
- Volunteers
- 588 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Failure, Chronic
The Everolimus-Transplant Exit Strategy Trial (E-TEST)
The purpose of this study is to test the safety and effectiveness of everolimus (Zortress®) in preventing antibody formation in patients with chronic failing kidney transplants. Everolimus (Zortress®) is approved by the U.S.
- Trial name
- E-TEST (NCT01636466)
- Testing
- Everolimus
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Ashtar Chami
Renal Transplant Recipients With Anti-HLA Antibodies
A Prospective, Global, Multi-center, Treatment Registry Study of Intravenous Immunoglobulin Maintenance Therapy in Alloantibody Positive Renal Allograft Recipients
The purpose of this treatment registry study is to determine if monthly infusions of Intravenous Immunoglobulin (IVIg) for 6 months will neutralize donor specific antibodies that are thought to be responsible for chronic…
- Trial name
- DSA (NCT02115503)
- Where
- 8 sites in United States
- Volunteers
- 52 people
- Sponsor
- Databean
Proteinuria
Belatacept Conversion in Proteinuric Kidney Transplant Recipients
Background: Proteinuria develops in about 30% of kidney transplant recipients and is a strong predictor of graft loss. The amount of proteinuria has a direct correlation with the risk of graft failure.
- Trial name
- NCT02327403
- Testing
- Belatacept
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Brigham and Women's Hospital
Renal Transplant Rejection
Induction Therapy With Autologous Mesenchymal Stem Cells for Kidney Allografts
The goal of this study is to evaluate autologous MSCs as an alternative for antibody induction therapy in renal transplantation.
- Trial name
- NCT00658073
- Testing
- Kidney transplantation with MSCs infusion, kidney transplantation without MSC infusion
- Where
- China
- Volunteers
- 165 people
- Sponsor
- Fuzhou General Hospital
Kidney Transplant
A Study of Factors That Affect Long-Term Kidney Transplant Function
The causes of deterioration of transplanted kidney function are poorly understood. The purpose of this study is to determine the disease processes that cause transplanted kidney dysfunction and loss in patients who received a…
- Trial name
- DeKAF (NCT00270712)
- Where
- 7 sites in United States, Canada
- Volunteers
- 3,175 people
- Sponsor
- University of Minnesota
Kidney Transplantation
Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy
The 3C study is investigating whether reducing exposure to calcineurin inhibitors (by using more potent antibody induction treatment and/or an elective switch to sirolimus) can improve the function and survival of kidney…
- Trial name
- 3C (NCT01120028)
- Testing
- Alemtuzumab, Basiliximab, Sirolimus
- Where
- 20 sites in United Kingdom
- Volunteers
- 852 people
- Sponsor
- University of Oxford
Kidney Diseases
The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients
This study was done to find out which treatment, tacrolimus or sirolimus, leads to better long-term kidney function in kidney transplant patients.
- Trial name
- NCT00275535
- Testing
- Anti-thymocyte globulin, Mycophenolate mofetil, Prednisone
- Where
- United States
- Volunteers
- 165 people
- Sponsor
- Mayo Clinic
Kidney Failure, Transplant;Failure,Kidney
Kidney Transplant Outcome and Organ Acceptance Practice Pattern: A Nationwide Analyses in the US and France
Despite the considerable advances in short-term outcomes, kidney transplant recipients continue to suffer from late allograft failure, and little improvement has been made over the past 15 years.
- Trial name
- USFRKT (NCT03723668)
- Where
- 2 sites in United States, France
- Volunteers
- 94,017 people
- Sponsor
- Paris Translational Research Center for Organ Transplantation